In each group, the first children inoculated will receive the lowest doses and will be monitored for reactions before later participants are given higher doses.

Then, researchers will perform an interim analysis to determine which dose is safest and most effective for each age group.

Children in part two of the study will receive the doses selected by the analysis — or placebo shots consisting of salt water.

The children will be followed for a year, to look for side effects and measure antibody levels that will help researchers determine whether the vaccine is effective. The antibody levels will be the main indicator, but the researchers will also look for coronavirus infections, with or without symptoms.

Dr. Wohl said the study appeared well designed and likely to be efficient, but he questioned why the children were to be followed for only one year, when adults in Moderna’s study are followed for two years. He also said he was somewhat surprised to see the vaccine being tested in children so young this soon.

This content was originally published here.